167 related articles for article (PubMed ID: 21882282)
21. Combined Genetic and Chromosomal Characterization of Wilms Tumors Identifies Chromosome 12 Gain as a Potential New Marker Predicting a Favorable Outcome.
Haruta M; Arai Y; Okita H; Tanaka Y; Takimoto T; Sugino RP; Yamada Y; Kamijo T; Oue T; Fukuzawa M; Koshinaga T; Kaneko Y
Neoplasia; 2019 Jan; 21(1):117-131. PubMed ID: 30530054
[TBL] [Abstract][Full Text] [Related]
22. Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia.
Ma D; Chen Z; Patel KP; Mishra BM; Yao H; Abruzzo LV; Medeiros LJ; Wierda W; Keating M; Sargent R; Luthra R
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(Suppl 1):S17-24. PubMed ID: 22035742
[TBL] [Abstract][Full Text] [Related]
23. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
[TBL] [Abstract][Full Text] [Related]
24. Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution.
Rastegar B; Andersson N; Petersson A; Karlsson J; Chattopadhyay S; Valind A; Jansson C; Durand G; Romerius P; Jirström K; Holmquist Mengelbier L; Gisselsson D
Clin Cancer Res; 2023 Jul; 29(14):2668-2677. PubMed ID: 37140929
[TBL] [Abstract][Full Text] [Related]
25. Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours.
Natrajan R; Warren W; Messahel B; Reis-Filho JS; Brundler MA; Dome JS; Grundy PE; Vujanic G; Pritchard-Jones K; Jones C
J Clin Pathol; 2008 Jan; 61(1):95-102. PubMed ID: 17369505
[TBL] [Abstract][Full Text] [Related]
26. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ
J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937
[TBL] [Abstract][Full Text] [Related]
27. Involvement of germline DDX1-MYCN duplication in inherited nephroblastoma.
Fievet A; Belaud-Rotureau MA; Dugay F; Abadie C; Henry C; Taque S; Andrieux J; Guyetant S; Robert M; Dubourg C; Edan C; Rioux-Leclercq N; Odent S; Jaillard S
Eur J Med Genet; 2013 Dec; 56(12):643-7. PubMed ID: 24161495
[TBL] [Abstract][Full Text] [Related]
28. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
[TBL] [Abstract][Full Text] [Related]
29. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
[TBL] [Abstract][Full Text] [Related]
30. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
[TBL] [Abstract][Full Text] [Related]
31. Identification of limited regions of genetic aberrations in patients affected with Wilms' tumor using a tiling-path chromosome 22 array.
Benetkiewicz M; Díaz de Ståhl T; Gördör A; Pfeifer S; Wittmann S; Gessler M; Dumanski JP
Int J Cancer; 2006 Aug; 119(3):571-8. PubMed ID: 16496407
[TBL] [Abstract][Full Text] [Related]
32. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
[TBL] [Abstract][Full Text] [Related]
33. Regulation of CRABP-II expression by MycN in Wilms tumor.
Gupta A; Kessler P; Rawwas J; Williams BR
Exp Cell Res; 2008 Dec; 314(20):3663-8. PubMed ID: 18955045
[TBL] [Abstract][Full Text] [Related]
34. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.
Bown N; Cotterill SJ; Roberts P; Griffiths M; Larkins S; Hibbert S; Middleton H; Kelsey A; Tritton D; Mitchell C
Med Pediatr Oncol; 2002 Jan; 38(1):11-21. PubMed ID: 11835232
[TBL] [Abstract][Full Text] [Related]
35. Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study.
Gadd S; Huff V; Skol AD; Renfro LA; Fernandez CV; Mullen EA; Jones CD; Hoadley KA; Yap KL; Ramirez NC; Aris S; Phung QH; Perlman EJ
Cell Rep Med; 2022 Jun; 3(6):100644. PubMed ID: 35617957
[TBL] [Abstract][Full Text] [Related]
36. Gain of 1q is a marker of poor prognosis in Wilms' tumors.
Segers H; van den Heuvel-Eibrink MM; Williams RD; van Tinteren H; Vujanic G; Pieters R; Pritchard-Jones K; Bown N;
Genes Chromosomes Cancer; 2013 Nov; 52(11):1065-74. PubMed ID: 24038759
[TBL] [Abstract][Full Text] [Related]
37. Genetic changes of two Wilms tumors with anaplasia and a review of the literature suggesting a marker profile for therapy resistance.
Stock C; Ambros IM; Lion T; Zoubek A; Amann G; Gadner H; Ambros PF
Cancer Genet Cytogenet; 2002 Jun; 135(2):128-38. PubMed ID: 12127397
[TBL] [Abstract][Full Text] [Related]
38. Bilateral wilms tumor with TP53-related anaplasia.
Popov SD; Vujanic GM; Sebire NJ; Chagtai T; Williams R; Vaidya S; Pritchard-Jones K
Pediatr Dev Pathol; 2013; 16(3):217-23. PubMed ID: 23387809
[TBL] [Abstract][Full Text] [Related]
39. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors.
Hing S; Lu YJ; Summersgill B; King-Underwood L; Nicholson J; Grundy P; Grundy R; Gessler M; Shipley J; Pritchard-Jones K
Am J Pathol; 2001 Feb; 158(2):393-8. PubMed ID: 11159177
[TBL] [Abstract][Full Text] [Related]
40. Copy Number Variations in Wilms Tumor: A Pilot Study From India.
Rahiman EA; Singh M; Bhatia P; Kakkar N; Trehan A; Bansal D
J Pediatr Hematol Oncol; 2020 Jul; 42(5):e299-e304. PubMed ID: 31851072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
